0000 25714

ACTION AND DECISION LIST OU-1 PHASE III COMMENTS MEETING 15-MARCH-93 (HUMAN HEALTH RISK ASSESSMENT ISSUES)

ACTION ITEM		LEAD	DUE
1 0 1 1	COC ISSUE Finish review of Background Geochemical Report	EPA	ASAP
2 0	DATA QUALITY VALIDATION USABILITY ASSESSMENT		
2 1	Develop shells of table for presentation of SQLs and CRQLs	EG&G Gee	3/26
3 0	COC SELECTION ISSUE		
3 1	Develop shell of table for presentation of carcinogens	EG&G Gee	3/26

DECISIONS

ĩ

- 1 0 INGESTION OF GROUND WATER ISSUE
- 1 1 DOE will provide a case in the HHRA that will include Ingestion Inhalation and Dermal pathways
- 1 2 Inhalation and dermal contact exposures will be derived from standard showering scenario
- 1 3 Three cases will be presented in the HHRA
 - Case A Present case in report
 - Case B Scenario requested by CDH without mass balances
 - Case C Similar to Case B with the inclusion of fresh water make up and include mass balance calculations
- 2 0 DATA QUALITY VALIDATION USABILITY ASSESSMENT
- 2.1 The data to be used in the HHRA are interim data full Phase III data and second quarter of 1992 data
- 2.2 An investigation of toluene as a laboratory contaminant is to be addressed in the HHRA
- 2.3 Should toluene be a laboratory contaminant it may be addresses qualitatively
- 2 4 Other laboratory contaminants such as phthalates should be addressed if they are excluded from the COC process
- 2 5 SQLs and CRQIs are to be presented in the risk assessment with data summary tables to include Chemical SQL CRQL Range Average 95% Upper Confidence Limits
- 2 6 Present validations limitations data exclusions and a discussion of data usability for the risk assessment in the report
- 3 0 COC SELECTION ISSUES
- 3 1 The COC selection methodology must be thoroughly explained
- 3 2 Define Hot Spot as

Being located infrequently Related to a waste

In elevated concentrations

- 3 3 Discuss Hot Spots and present a summary table for Hot Spot data
- 3 4 COCs associated with the Hot Spots must be addressed in the report

- 3 5 Present medium specific tables paralleling the flow chart which details the discission points. Insure that the reader is provided documentation of the process. Tables are to include ≤ Back Ground % Risk Retained Excluded. The tables will explicitly identify Group A carcinogens. Acarcinogens eliminated will be discussed.
- 3 6 The discussion of COCs will be continued and Statistical flow methodology will also be discussed at the next meeting on 26 March 93 at 0830 at EG&G